Long-Term Data On Medtronic AAA Graft Prompts FDA Public Health Notice
This article was originally published in The Gray Sheet
Executive Summary
FDA says that new long-term data shows that the aneurysm-related mortality in patients treated with Medtronic's AneuRx abdominal aortic aneurysm (AAA) graft is "substantially higher" than the mortality rate for open surgical repair
You may also be interested in...
NEJM Study Touts Longer Lasting Survival Benefit Of Endovascular AAA Repair
The relative long-term benefits of endovascular repair versus invasive surgery for abdominal aortic aneurysms (AAA) may be greater than previously thought, according a study published Jan. 31 in the New England Journal of Medicine
Medtronic Cited For Late Postmarket Report; First “522” Action Under FDAMA
An FDA 1warning letter sent to Medtronic Sept. 27 is the agency's first enforcement action under its 1997 powers to compel device makers to collect specified postmarket surveillance data
AAA Endografts Show Early Promise In Lowering Mortality – Lancet Study
Longer-term follow-up is needed to confirm early clinical results showing a survival benefit for patients receiving endovascular aneurysm repair versus open surgery for abdominal aortic aneurysm treatment, according to an Aug. 25 Lancet study